PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0654-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION

REC-104/US Attorney Docket No. Olsson, Lennart First Inventor Affinity Small Molecules for the EPO Receptor Title

(Only for new nonprovisional applications under 37 CFR 1.53(b))

TRANSMITTAL

Express Mail Label No.

APPLICATION ELEMENTS	EU98503035
	ADDRESS TO: Box Patent Application
See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17)	Washington, DC 20231
1. L (Submit an original and a duplicate for fee processing)	7 CD-ROM or CD-R in duplicate, large table or Computer Program (<i>Appendix</i>)
2. Applicant claims small entity status. See 37 CFR 1.27.	8. Nucleotide and/or Amino Acid Sequence Submission
Specification [Total Pages 77] 3. (preferred arrangement set forth below)	(if applicable, all necessary) a
- Descriptive title of the invention	b. Specification Sequence Listing on:
- Cross Reference to Related Applications	i. CD-ROM or CD-R (2 copies); or
 Statement Regarding Fed sponsored R & D Reference to sequence listing, a table, 	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
or a computer program listing appendix	ii. 🔽 paper
 Background of the Invention Brief Summary of the Invention 	c. Statements verifying identity of above copies
- Brief Description of the Drawings (<i>if filed</i>)	ACCOMPANYING APPLICATION PARTS
- Detailed Description	Assignment Papers (cover sheet & document(s))
- Claim(s) - Abstract of the Disclosure	10. 37 CFR 3.73(b) Statement Power of
, · · · · · · · · · · · · · · · · · · ·	(when there is an assignee) — Attorney
4. Drawing(s) (35 U.S.C. 113) [Total Sheets 17]	11. English Translation Document (if applicable) Information Disclosure Copies of IDS
5. Oath or Declaration [Total Pages]	Statement (IDS)/PTO-1449 Citations
a. Newly executed (original or copy)	13. Preliminary Amendment
b. Copy from a prior application (37 CFR 1.63 (d)) (for continuation/divisional with Box 18 completed)	14. Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s)	15. Certified Copy of Priority Document(s) (if foreign priority is claimed)
named in the prior application, see 37 CFR	16. Nonpublication Request under 35 U.S.C. 122
1.63(d)(2) and 1.33(b).	(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
6. Application Data Sheet. See 37 CFR 1.76	17. Other:
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,	
or in an Application Data Sheet under 37 CFR 1.76:	
Continuation Divisional Continuation-in-part (CIP)	of prior application No.:/
Prior application information: Examiner:	Group Art Unit:
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.	
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.	
19. CORRESPONDENCE ADDRESS	
Customer Number or Bar Code Label	or Correspondence address below
Name 30869	
	
Address	
	tate Zip Code
Country Teleph	
	
Name (Print/Type) Bertram Bowland	Registration No. (Attorney/Agent) 20,015
Signature Dert framan	Date 7/2/03

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.